BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chandler A, Bartelstein MK, Fujiwara T, Antonescu CR, Healey JH, Vaynrub M. Anti-IL17 antibody Secukinumab therapy is associated with ossification in giant cell tumor of bone: a case report of pathologic similarities and therapeutic potential similar to Denosumab. BMC Musculoskelet Disord 2021;22:320. [PMID: 33794838 DOI: 10.1186/s12891-021-04182-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Damiani G, Odorici G, Pacifico A, Morrone A, Conic RRZ, Davidson T, Watad A, Pigatto PDM, Colombo D, Malagoli P, Fiore M. Secukinumab Loss of Efficacy Is Perfectly Counteracted by the Introduction of Combination Therapy (Rescue Therapy): Data from a Multicenter Real-Life Study in a Cohort of Italian Psoriatic Patients That Avoided Secukinumab Switching. Pharmaceuticals 2022;15:95. [DOI: 10.3390/ph15010095] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
2 Tsukamoto S, Mavrogenis AF, Kido A, Errani C. Current Concepts in the Treatment of Giant Cell Tumors of Bone. Cancers (Basel) 2021;13:3647. [PMID: 34359548 DOI: 10.3390/cancers13153647] [Reference Citation Analysis]